Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2
Journal of General Virology · 2023
DOI: 10.1099/jgv.0.001865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of General Virology, 2023. Verfasst von Mark Thursz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Digestion and Reproduction, Imperial College, London W2 1NY, UK. Hauptthemen laut MEDLINE: COVID-19, RNA Viruses. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, European Commission.
Abstract (Originalsprache)
The 2',5'- oligoadenylate synthetase (OAS) – ribonuclease L (RNAseL) - phosphodiesterase 12 (PDE12) pathway is an essential interferon-induced effector mechanism against RNA virus infection. Inhibition of PDE12 leads to selective amplification of RNAseL activity in infected cells. We aimed to investigate PDE12 as a potential pan-RNA virus antiviral drug target and develop PDE12 inhibitors that elicit antiviral activity against a range of viruses. A library of 18 000 small molecules was screened for PDE12 inhibitor activity using a fluorescent probe specific for PDE12. The lead compounds (CO-17 or CO-63) were tested in cell-based antiviral assays using encephalomyocarditis virus (EMCV), hepatitis C virus (HCV), dengue virus (DENV), West Nile virus (WNV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in vitro . Cross reactivity of PDE12 inhibitors with other PDEs and in vivo toxicity were measured. In EMCV assays, CO-17 potentiated the effect of IFNα by 3 log 10 . The compounds were selective for PDE12 when tested against a panel of other PDEs and non-toxic at up to 42 mg kg −1 in rats in vivo . Thus, we have identified PDE12 inhibitors (CO-17 and CO-63), and established the principle that inhibitors of PDE12 have antiviral properties. Early studies suggest these PDE12 inhibitors are well tolerated at the therapeutic range, and reduce viral load in studies of DENV, HCV, WNV and SARS-CoV-2 in human cells and WNV in a mouse model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism, Digestion and Reproduction, Imperial College, London W2 1NY, UK.
- Present address: Directorate of Research, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
- UK Health Security Agency, Porton Down, Salisbury, SP4 0JG, UK.
- University of Nicosia Medical School, Nicosia, Cyprus.
- RioTech Pharmaceuticals, 49 Arrivato Plaza, St Helens, WA10 1GH, UK.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-1019, USA.
Förderung
- Wellcome Trust
- European Commission
Zitieren
APA
Thursz, M., Sadiq, F., Tree, J. A., Karayiannis, P., Beasley, D. W. C., Dejnirattisai, W., Mongkolsapaya, J., Screaton, G., Wand, M., Elmore, M. J., Carroll, M. W., Matthews, I., & Thomas, H. (2023). Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2. Journal of General Virology. https://doi.org/10.1099/jgv.0.001865
Vancouver
Thursz M, Sadiq F, Tree JA, Karayiannis P, Beasley DWC, Dejnirattisai W, et al. Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2. Journal of General Virology. 2023. doi:10.1099/jgv.0.001865
BibTeX
@article{Thursz2023,
author = {Thursz, Mark and Sadiq, Fouzia and Tree, Julia A and Karayiannis, Peter and Beasley, David W C and Dejnirattisai, Wanwissa and Mongkolsapaya, Juthathip and Screaton, Gavin and Wand, Matthew and Elmore, Michael J and Carroll, Miles W and Matthews, Ian and Thomas, Howard},
title = {Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2},
journal = {Journal of General Virology},
year = {2023},
doi = {10.1099/jgv.0.001865}
}
EUVIMED